There is widespread demand for biomedical automation in my country.

The pharmaceutical industry plays a crucial role in protecting and improving people’s health, enhancing the quality of life, promoting economic development, and social progress, and has therefore always been a focus of national attention. With the acceleration of China’s urbanization process, rapid population aging, and national healthcare system reforms, China’s pharmaceutical industry has maintained rapid growth in recent years.

China’s Broad Demand for Biopharmaceutical Automation

Additionally, to meet the continuously rising standards of GMP, FDA, and other regulations, pharmaceutical companies need to continuously improve and update their process technologies and production conditions. The introduction of automated control systems can significantly improve the quality and efficiency of drug production, reduce production risks, and maximize compliance with GMP, FDA, and other standards for drug production. Under the backdrop of pharmaceutical industry development and mandatory GMP certification, major pharmaceutical companies in China have increased their fixed asset investment scale in recent years. According to data from the National Bureau of Statistics, from 2006 to 2013, China’s pharmaceutical manufacturing industry maintained rapid growth in fixed asset investment, with a total fixed asset investment of 452.683 billion yuan in 2013, achieving a compound annual growth rate of 29% over the past seven years.

In the field of biotechnology, with the cross-penetration of science and technology, industrial automation technology has been widely applied in microbiology. With in-depth research on large-scale microbial cultivation technology and understanding of the time-varying, diversity, coupling, and uncertainty of fermentation process parameters, modern microbiology has established mathematical models based on process dynamics and introduced a series of modern control theories such as expert systems, fuzzy control, neural networks, and chaos theory to achieve process management and optimization, while reducing energy and raw material consumption. The combination of industrial automation technology and microbiology has driven the biotechnology industry towards scale and sustainability. As a major driving force of international scientific and technological development today, the biotechnology industry has significant strategic importance in addressing major issues faced by humanity, such as population, health, food, energy, and the environment.

Facing the urgent need for the integration of the pharmaceutical and biotechnology industries with automation technology, large pharmaceutical companies hope to form large-scale production through increased fixed asset investment, further reducing unit fixed costs and creating industry competition barriers, pushing some small and medium competitors out of the market, and increasing market concentration and market share. It is expected that in the coming years, pharmaceutical companies’ fixed asset investment will continue to maintain a high growth rate. Some institutions have predicted the market demand for the pharmaceutical industry automation sector. Based on the fixed asset investment of 452.683 billion yuan in China’s pharmaceutical industry in 2013, and assuming that the industrial automation investment in the pharmaceutical industry accounts for 5% of the pharmaceutical industry’s fixed asset investment, and a compound annual growth rate of 20% in fixed asset investment, it is estimated that by 2017, the market demand for China’s pharmaceutical industry automation sector will grow to 46.934 billion yuan. The rapid development and industrial upgrading of the pharmaceutical industry, as well as the fixed asset investment driven by market competition needs, will bring new development opportunities to China’s pharmaceutical industry automation sector.

In recent years, due to the rapid development of the pharmaceutical industry, increasingly stringent drug production and quality management regulations, and other factors, the demand for automation equipment by pharmaceutical companies has been increasing year by year, promoting the healthy development of the industrial automation sector. Although there is a certain gap between China’s automation level and advanced foreign levels, through the digestion and absorption of advanced foreign technology and independent innovation, China has gradually mastered the core technology of pharmaceutical industry automation, narrowing the gap with foreign countries, and some technologies have approached the world’s advanced level, basically meeting the needs of domestic pharmaceutical companies.